BI(Boehringer Ingelheim)
Boehringer Ingelheim and Peking University established a strategic partnership in May 2017 to jointly advance early science innovation across a range of areas of high medical need including cancer, cancer immunology and immune modulation, respiratory, cardiometabolic, and central nervous system diseases. It comprises project-based research, a joint post-doctorate fellowship program, and a number of Boehringer Ingelheim endowed investigators, and aims to strengthen Boehringer Ingelheim’s portfolio of early and unique pipeline projects supporting the company’s aspiration to be at the forefront of science and technology and deliver more first-in-class medicines with breakthrough potential, taking Boehringer Ingelheim’s R&D efforts in Asia to the next level.
About Boehringer Ingelheim
Innovative medicines for people and animals have for more than 130 years been what the research-driven pharmaceutical company Boehringer Ingelheim stands for. Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies and to this day remains family-owned. Day by day, some 53, 500 employees create value through innovation for the three business areas of human pharmaceuticals, animal health, and biopharmaceutical contract manufacturing. In 2023, Boehringer Ingelheim achieved net sales of around 25.6 billion euros. With more than six billion euros, R&D expenditure corresponds to 25.1% of net sales.
More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com or in the annual report: http://annualreport.boehringer-ingelheim.com